Lupin Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Lupin Pharmaceuticals (Baltimore, MD): 35 reconciled FDA prescription therapies, $380.8M 2024 CMS Part D & Medicaid spend, and $7,217 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBaltimore, MD
Reconciled FDA Portfolio Therapies35
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$380.8M
2024 Medicare Part D Spend$294.2M
2024 Medicaid Spend$86.6M
California HCAI SB 17 FilingsSpecialty launch notice ($7,217 intro WAC)